Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 202,560,400
  • Shares Outstanding, K 2,044,000
  • Annual Sales, $ 46,660 M
  • Annual Income, $ 14,850 M
  • EBIT $ 13,245 M
  • EBITDA $ 21,628 M
  • 60-Month Beta 0.56
  • Price/Sales 4.40
  • Price/Cash Flow 8.80
  • Price/Book 4.60

Options Overview Details

View History
  • Implied Volatility 20.53% ( +2.21%)
  • Historical Volatility 14.83%
  • IV Percentile 79%
  • IV Rank 62.93%
  • IV High 25.21% on 04/19/24
  • IV Low 12.60% on 05/16/24
  • Put/Call Vol Ratio 0.15
  • Today's Volume 1,406
  • Volume Avg (30-Day) 1,444
  • Put/Call OI Ratio 1.30
  • Today's Open Interest 55,585
  • Open Int (30-Day) 48,842

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.84
  • Number of Estimates 5
  • High Estimate 1.95
  • Low Estimate 1.77
  • Prior Year 1.53
  • Growth Rate Est. (year over year) +20.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.82 +0.01%
on 12/18/24
105.97 -8.63%
on 11/29/24
-6.21 (-6.03%)
since 11/18/24
3-Month
96.82 +0.01%
on 12/18/24
117.36 -17.49%
on 10/18/24
-19.14 (-16.50%)
since 09/18/24
52-Week
92.35 +4.85%
on 04/18/24
120.92 -19.92%
on 08/30/24
-1.39 (-1.42%)
since 12/18/23

Most Recent Stories

More News
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.7420 (-3.76%)
NVS : 96.83 (-2.29%)
ONC.TO : 1.10 (-2.65%)
PFE : 25.89 (-2.04%)
GSK : 33.69 (-1.58%)
BMY : 56.84 (-1.41%)
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™

/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical...

NVS : 96.83 (-2.29%)
Top Stock Reports for Mastercard, Procter & Gamble & Novartis

Thursday, December 12, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard...

SONY : 20.91 (-3.77%)
MSI : 462.68 (+0.20%)
MA : 519.96 (-2.08%)
PG : 169.08 (-0.73%)
ENB : 40.50 (-2.17%)
NVS : 96.83 (-2.29%)
Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity

/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the three recipients of its inaugural Health Equity Initiative. Based on the...

NVS : 96.83 (-2.29%)
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows

Wells Fargo highlighted the agreement’s $1.9 billion milestone potential, 40% U.S. profit-sharing terms, and double-digit royalties on ex-U.S. sales.

PTCT : 45.46 (-3.32%)
NVS : 96.83 (-2.29%)
2 Dividend Stocks to Buy and Hold Forever

No income investor buys shares of a dividend-paying company expecting that it will suspend its distributions at some point. Quite the contrary, dividend investors want those payouts to keep going and growing...

V : 309.78 (-2.68%)
NVS : 96.83 (-2.29%)
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer

Novartis NVS announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a broad population.The EC has approved Kisqali in combination with an aromatase...

LLY : 764.71 (-1.79%)
NVS : 96.83 (-2.29%)
PFE : 25.89 (-2.04%)
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View

This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia drug Hympavzi (marstacimab). AstraZeneca’s AZN Tagrisso was recommended...

AZN : 64.64 (-3.78%)
JNJ : 144.75 (-1.13%)
LLY : 764.71 (-1.79%)
NVS : 96.83 (-2.29%)
PFE : 25.89 (-2.04%)
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

Novartis NVS announced that it has increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with...

NVS : 96.83 (-2.29%)
GILD : 90.69 (-2.27%)
PFE : 25.89 (-2.04%)
MEDIA STATEMENT - Novartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTO™

/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide...

NVS : 96.83 (-2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy,...

See More

Key Turning Points

3rd Resistance Point 100.21
2nd Resistance Point 99.53
1st Resistance Point 98.18
Last Price 96.83
1st Support Level 96.15
2nd Support Level 95.47
3rd Support Level 94.12

See More

52-Week High 120.92
Fibonacci 61.8% 110.01
Fibonacci 50% 106.63
Fibonacci 38.2% 103.26
Last Price 96.83
52-Week Low 92.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar